TABLE 2.
[18F]FDG-PET radiomics studies focusing on clinical outcome prognostication
| Purpose | Imaging | Patients | Training/Test | Segmentation | Features | |
|---|---|---|---|---|---|---|
| Parvez et al. | Aggressive NHL: treatment response, OS, DFS | [18F]FDG-PET | 66 | No | Semi-automatic | Shape, Histogram, GLCM, GLRLM, GLSZM, NGTDM |
| Milgrom et al. | Hodgkin: Refractory disease | [18F]FDG-PET | 251 | Yes (internal) | Semi-automatic | Shape, Histogram, GLCM |
| Lue et al. | Hodgkin: OS, PFS | [18F]FDG-PET | 42 | No | Semi-automatic | Histogram, GLCM, GLRLM, GLSZM, NGTDM, NGLDM, Wavelet |
| Mayerhoefer et al. | MCL: PFS | [18F]FDG-PET | 107 | Yes (internal) | Semi-automatic | Histogram, GLCM |
| Aide et al. | DLBCL: PFS, OS | [18F]FDG-PET | 82 | No | Semi-automatic | Histogram, GLCM, GLSZM |
| Aide et al. | DLBCL: EFS | [18F]FDG-PET | 132 | Yes (internal) | Semi-automatic | Histogram, GLCM, GLSZM |
| Wand et al | Natural killer-/T-cell lymphoma: PFS, OS | [18F]FDG-PET | 110 | Yes (internal) | Semi-automatic | Shape, Histogram, GLCM, GLRLM, GLSZM, NGLDM |
NHL, Non-Hodgkin lymphoma; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; GLCM, gray-level co-occurrence matrix; GLRLM, gray-level run-length matrix; GLSZM, gray-level size-zone matrix; NGTDM, neighborhood gray-tone difference matrix; NGLDM, neighborhood gray-level dependence matrix